Clinical Trial Update: A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase II study evaluating safety and efficacy of ALX-0061 in systemic lupus erythematosus has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• ALX-0061 (ALX-0061)

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2019-02-06